Jan 24, 2019
BridgeBio bags USD 299 Million for genetic diseases BridgeBio Pharma has received a USD299.2 million for its progress in genetic disease pipeline. This includes assets in preclinical and clinical development. Several therapeutic areas are being taken under the consideration of the pharma. Also, th...
Read More...
Discover How Learning Disability Treatment Landscape is Evolving with the Emergence of Digital Assistant Technologies
Jul 04, 2025
A New Era for Multiple Myeloma Treatment: Bispecific Antibodies Enter the Fray
Jun 10, 2025
LEQEMBI: A New Hope for Alzheimer’s Disease Patients
Feb 12, 2025
Newsletter/Whitepaper